Rival For Opdivo As Keytruda Launches For NSCLC In Japan At Same Daily Price
Executive Summary
Opdivo has a new rival in the lung cancer setting in Japan following the reimbursement and launch of Keytruda at the same daily price.
You may also be interested in...
Opdivo, Keytruda Hit Again As Japan Revises Prices
Immuno-oncology drugs Opdivo and Keytruda will have their prices cut in the next regular Japanese price revision in April, while some other novel and big-selling products will also feel the heat under a revised framework.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.